Skip to content

Main Navigation

Latham BioPharm Group logo

978.266.9151
  • About Us
    • Who We Are / Mission and Values
    • Business Model / Value Proposition
    • Leadership Team
  • Services
    • Non-dilutive Funding
      • Government Relations
      • Proposal Development
      • Post-award Support
      • Contract Compliance
    • Product Development
      • CMC
      • Regulatory
      • Clinical
      • Nonclinical
      • Discovery
      • Quality
      • Project Management
      • Vendor Management
    • Strategic Consulting
      • Strategic Planning
      • Financial Modeling
      • Market Research
      • Supply Chain Network Development & Optimization
      • Market Access / Launch
      • Due Diligence
      • Technology Scouting
  • Expertise
    • Product Types
      • Vaccines
      • Therapeutics
      • Small Molecules
      • Cell & Gene Therapies
      • Medical Devices
      • Diagnostics
      • Digital Health
      • MCMs
      • Animal Health
    • Sectors
      • LBG Biologics
      • LBG Animal Health
      • LBG Pharma
      • LBG MD&D (Medical Devices, Diagnostics, and Digital Health)
  • Media / Collateral
    • Press Releases
    • News
    • Collateral
    • Case Studies
  • Careers
    • Working at LBG
    • Current Opportunities
  • Contact Us
    • Locations
    • Request a Meeting

Press Releases

  • Press Releases
  • News
  • Collateral
  • Case Studies

Press Releases

Press Release

Sia/LBG Receives Supplemental Grant to Expand Features for Global Health Cost Model Platform

View Press Release
Press Release

Latham BioPharm Group Awarded NIAID Preclinical Services IDIQ Contract Valued at up to $30 Million

View Press Release
Press Release

Latham BioPharm Group Awarded Grant to Develop a Global Health Cost Model Platform

View Press Release
Press Release

Latham BioPharm Group Expands Offering into Digital Health

View Press Release
Press Release

Sia Partners Announces Acquisition of Latham BioPharm Group

View Press Release
Press Release

Latham BioPharm Group Announces Publication of Team Member’s Paper in Leading Scientific Journal

View Press Release
Press Release

Latham BioPharm Group Enhances its Discovery, Nonclinical, and Animal Health (DNA) Service Sector

View Press Release
Press Release

Latham BioPharm Group enhances its Non-dilutive Funding capabilities – adds contract compliance offering.

View Press Release
Press Release

Latham BioPharm Group Continues its Expansion

View Press Release
Press Release

Latham BioPharm Group adds Dr. Thijs Beuming and expands consulting offering to include In Silico Drug Discovery services.

View Press Release
12
Next Page »

Interested in our services?

Contact us today to set up an appointment.

Get Started

Footer Navigation

  • About Us
  • Services
    • Non-dilutive Funding
    • Product Development
    • Strategic Consulting
  • Expertise
    • Product Types
    • Sectors
  • Media / Collateral
    • Press Releases
    • News
    • Collateral
    • Case Studies
  • Careers
  • Contact Us

Contact Information

Follow Us
  • LinkedIn
Latham BioPharm Group
Phone: 978.266.9151
Email: Email Us

© Latham BioPharm Group. All rights reserved. | Privacy Policy

This site uses cookies to give you the best, most relevant experience. By continuing to browse the site you are agreeing to our use of cookies. You can find out more about which cookies we are using or switch them off in .

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.